ShareValue scores for MAP.AU: Valuation 60, Quality 39, Growth 56, Health 42.

MAP.AU
ASX

Microba Life Sciences Ltd

A$0.05(-2.04%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

7% to 18%
Valuation
60
Fair Value
Price vs Value
Quality
39
Weak
Business Strength
Growth
56
Moderate
Revenue & Earnings
Health
42
Moderate
Financial Stability
Momentum
19
Bearish
Price Trend

Company Details

About

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026